Provided by Tiger Fintech (Singapore) Pte. Ltd.

Illumina

78.17
+0.29000.37%
Post-market: 78.230.0600+0.08%16:31 EDT
Volume:1.09M
Turnover:85.49M
Market Cap:12.37B
PE:-10.16
High:79.00
Open:77.40
Low:77.08
Close:77.88
Loading ...

Cathie Wood Explains AI Growth Catalysts for Illumina (ILMN)

Insider Monkey
·
20 Feb

Grail Inc expected to post a loss of $7.05 a share - Earnings Preview

Reuters
·
19 Feb

NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight

Zacks
·
19 Feb

BofA Securities Cuts Price Target on Illumina to $90 From $110, Keeps Underperform Rating

MT Newswires Live
·
18 Feb

Illumina Faces Potential Downside: Sell Rating and Cautious Outlook Amidst Market Challenges

TIPRANKS
·
18 Feb

More on Illumina, the Nasdaq-listed genetic testing firm named in PM Wong’s Budget 2025 speech

Jovi Ho
·
18 Feb

Genetics Tools Face Fund Cuts -- Barron's

Dow Jones
·
15 Feb

Carl Icahn's Strategic Moves: A Closer Look at Icahn Enterprises LP

GuruFocus.com
·
15 Feb

Illumina Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
15 Feb

BRIEF-Carl Icahn Cuts Shared Share Stake In Southwest Gas Holdings, Illumina

Reuters
·
15 Feb

Illumina Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
14 Feb

Calvin Klein blacklisting sends chill through US business in China

Financial Times
·
14 Feb

Jim Cramer on China’s Crackdown on Illumina (ILMN): “There Are Two Other Companies That Do What They Do”

Insider Monkey
·
14 Feb

10x Genomics Shares Tumble on Fear Over Cuts to NIH -- Barrons.com

Dow Jones
·
13 Feb

Trump's Cuts to Medical Research Are Hurting These Stocks -- Barrons.com

Dow Jones
·
13 Feb

Trickle-down effect of NIH funding battle worries healthcare analysts and medical experts

Yahoo Finance
·
13 Feb

Illumina Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
13 Feb

Here's Why Illumina (ILMN) is a Strong Growth Stock

Zacks
·
12 Feb

PacBio (PACB) Q4 Earnings Report Preview: What To Look For

StockStory
·
12 Feb

Illumina Inc. Stock Sheds 4.1%, Underperforms Competitors

Dow Jones
·
12 Feb